Sindroxocin IV Infusion 2 mg/ml

Sindroxocin IV Infusion 2 mg/ml Uses, Dosage, Side Effects, Food Interaction and all others data.

Trade Name Sindroxocin IV Infusion 2 mg/ml
Generic Doxorubicin Hydrochloride
Weight 2 mg/ml
Type IV Infusion
Therapeutic Class Cytotoxic Chemotherapy
Manufacturer BOTS Pvt. Limited
Available Country Bangladesh
Last Updated: October 19, 2023 at 6:27 am
Sindroxocin IV Infusion 2 mg/ml
Sindroxocin IV Infusion 2 mg/ml

Uses

Doxorubicin is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer: After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.

Dosage

Sindroxocin IV Infusion 2 mg/ml dosage

Administer Doxorubicin at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion related reactions occur, increase rate of infusion to complete administration over 1 hour. Do not administer as bolus injection or undiluted solution. Ovarian cancer: 50 mg/m2 IV every 4 weeks AIDS-related Kaposi’s Sarcoma: 20 mg/m2 IV every 3 weeks Multiple Myeloma: 30 mg/m2 IV on day 4 following bortezomib

Side Effects

Leucopenia, thrombocytopenia, nausea, vomiting, diarrhoea. Rarely facial flushing, rash, alopecia. Blurred vision, headache, seizures, paraesthesia, confusion, malaise, lethargy, skin pigmentation.

Precaution

Elderly, children, hepatic impairment. Monitor blood counts and ECG.

Interaction

Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.

Pregnancy & Breastfeeding use

Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Contraindication

Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.

Special Warning

Hepatic Impairment- serum-bilirubin: 12-30 mcg/ml: Half the normal dose; serum-bilirubin: >30 mcg/ml: Quarter of the usual dose.

Acute Overdose

Acute overdosage may increase the toxic effects of mucositis, leukopenia and thrombocytopenia. Treatment includes hospitalisation of the severely myelosuppressed patient, antimicrobials, platelet transfusions and symptomatic treatment of mucositis. Use of haemopoietic growth factor (G-CSF, GM-CSF) may be considered. Cumulative dosage increases risk of cardiomyopathy and resultant congestive heart failure which may be managed with digitalis preparations, diuretics, and after load reducers such as ACE inhibitors.

Storage Condition

Powder for injection: Store at 15-30°C. Solution for injection & liposomal formulations: Refrigerate at 2-8°C. Do not freeze.

Innovators Monograph

You find simplified version here Sindroxocin IV Infusion 2 mg/ml


*** Taking medicines without doctor's advice can cause long-term problems.
Share